Coded SKU names — how research-peptide vendors hide FDA-cited compounds in plain sight

Quick answer

Several research-peptide vendors list FDA-cited compounds — Retatrutide, Tirzepatide, Semaglutide — under coded SKU names like GLP-3, R-10mg, T-30mg, Sema-1, and Cagri. The pattern is documented across at least two vendors in our cohort and serves three converging purposes: evading pharmaceutical-trademark text on the catalog, evading ad-keyword filters at Google and Meta, and diversifying the brand surface a future FDA warning letter would have to cite by name.

What we documented

In Round 66/67 of our audit cycle we ran two parallel investigations that produced compatible findings.

Particle Peptides (particlepeptides.com) lists Retatrutide on the public catalog as GLP-3. The product page itself names the compound as "GLP-3 (LY3437943)" — LY3437943 is the chemical identifier Eli Lilly uses internally and on every clinical trial registration for Retatrutide. The mapping is unambiguous on Particle's own copy. There is no public note on the listing flagging the alias for buyers searching the term "Retatrutide."

Summit Biotech (summitbiotechusa.com) ships eight different FDA-cited compounds under coded SKU names. We captured the catalog through the Supabase API the storefront itself queries — the same endpoint the site's own JavaScript hits to populate the product grid. Forty in-stock products at capture time. The codenamed subset:

Display name	Actual compound	Vial size	Price	Per-mg
Sema-1	Semaglutide	10mg	$50	$5.00/mg
R-10mg	Retatrutide	10mg	$55	$5.50/mg
T - 30mg	Tirzepatide	30mg	$65	$2.17/mg
T - 60mg	Tirzepatide	60mg	$100	$1.67/mg
Cagri	Cagrilintide	5mg	$45	$9.00/mg
Tesa 20mg	Tesamorelin	20mg	$90	$4.50/mg
Tesa5Ipa5	Tesamorelin / Ipamorelin blend	5mg + 5mg	$50	—
**-31 - 10mg	SS-31 (page note: "Previously known as SS - 31")	10mg	$40	$4.00/mg

Source: Summit Biotech catalog ID fbb34a1e-e17b-4b7b-8d81-e44749337e8d lists Sema-1 at $50 / 10mg vial; ID cd49626e-6b5b-4089-8a2b-12cdb4da2cb8 lists R-10mg at $55 / 10mg. Both records carry Janoshik COA links (tests/93072 and tests/150000 respectively) whose filename slugs on the COA URL spell out the real compound — sema10mg_OZ101201 and RT10White_cap — even when the product display name does not.

The identification of compound from coded name is not a guess. Each Summit Biotech SKU's COA URL contains the lab's filename for the sample, which is keyed on the actual molecule. R-10mg resolves to a Janoshik test for retatrutide. T - 30mg resolves to Tirzepatide_30mg_Orange_cap. The vendor has obscured the display name but not the COA URL.

Why operators do this

Three motivations stack. They are not mutually exclusive — a vendor gets all three benefits from one rename.

1. Pharmaceutical-trademark evasion

Eli Lilly has trademarked Retatrutide-adjacent commercial names and holds patents covering the Retatrutide molecule under its LY3437943 identifier. Tirzepatide is sold by Lilly as Mounjaro and Zepbound; Semaglutide is sold by Novo Nordisk as Ozempic and Wegovy. A research-peptide catalog that prints "Tirzepatide" in the SKU display name is one search-and-seizure step from a cease-and-desist in any market where the compound is patent-protected. A catalog that prints "T - 30mg" is not — there is nothing trademarked about the letter T.

This is the same logic that drove the 2024 FDA warning letters collected in Foley & Lardner's December 2024 write-up: the agency targeted "GLP-1 providers" by their copy and SKU labels, not by the underlying chemistry. The codename pattern is a direct response — strip the copy of the cited terms and the warning-letter template no longer matches.

2. Google / Meta ad-keyword filter evasion

Google Ads and Meta Ads both maintain blocklists for prescription-only pharmaceutical names. "Tirzepatide", "Semaglutide", and (more recently) "Retatrutide" are flagged terms — campaigns containing them are auto-rejected or shadow-throttled. A catalog page titled T - 30mg passes the keyword filter at submission time. Whether the buyer can still find the product is a different question — most click-through arrives via SEO on the compound's actual name elsewhere on the site (blog posts, FAQ, COA filenames), or via brand-direct traffic.

This is the lowest-friction explanation. It does not require any regulatory awareness on the operator's part, just the experience of having had three Google Ads accounts disabled.

3. FDA-warning-letter risk diversification

The December 10, 2024 FDA warning letter to Summit Research Peptides (letter 695607) specifically cited Tirzepatide and Semaglutide by name on the vendor's website. The cited entity reorganized to summitbiotechusa.com afterwards — the version we audited — and the catalog's SKU labels no longer print those names. The display name is T - 30mg. The chemistry is unchanged. The next FDA reviewer parsing the catalog for trademarked compound names finds none.

We are not asserting motive on the operator's part. We are asserting the operational effect: the codename rebrand removes the pharmaceutical-trademark text from the surface a warning letter templates cites. Whether the rebrand was prompted by the prior letter or coincidental is impossible to determine without subpoena. The post-enforcement timing is the data point we have.

Per-mg pricing on Retatrutide across vendors

The four-vendor comparison below uses the actual catalog prices our pricing pipeline captured in May 2026. The codename vendors are not materially cheaper than the named-listing vendors at the high end — but Summit Biotech's R-10mg is the cheapest Retatrutide per-mg in our entire seven-vendor index.

The two coloured bars are the codename vendors. Particle's GLP-3 sits at the top of the per-mg curve; Summit Biotech's R-10mg sits at the bottom. The codename pattern correlates with neither above-market nor below-market pricing — it is independent of price positioning, which is consistent with the trademark-and-keyword-filter explanation rather than a predatory-pricing explanation.

How to detect coded catalogs as a buyer

Three checks, all reproducible without vendor cooperation.

Check the COA URL, not the product display name. The COA filename is keyed on the chemistry, not on the marketing label. If the SKU is called R-10mg but the COA URL is janoshik.com/tests/150000-RT10White_cap_…, the molecule is Retatrutide regardless of how the catalog presents it. This is the single highest-yield check — operators rebrand the SKU label but rarely rename the COA URL because the lab assigned the filename, not the vendor.

Search the product detail page for the chemical identifier. Many codenamed listings still print the chemical or research identifier inline — Particle's GLP-3 page literally writes "(LY3437943)" in the copy. Tirzepatide listings often print "LY3298176"; Semaglutide listings often print "NN9535" or "NN9924". A single grep for the identifier on the product page resolves the alias.

Compare the SKU mass / price ratio against the named market. If a codenamed SKU lines up suspiciously closely with the per-mg curve of a named compound on other vendors, the codename probably maps to that compound. A vendor selling R-10mg at $5.50/mg sits exactly in the Retatrutide pricing band; that is not random.

Single-vendor disclosures are useful but limited. We've documented hostname-aliasing as a separate evasion pattern — codename catalogs are the SKU-level analog. Both share the underlying incentive structure: operators reduce what a regulator's automated parser can match on, while leaving the chemistry visible enough to the buyer who knows what to search for.

Implications

The codename pattern matters for three audiences.

For buyers, the alias risk is informational asymmetry. A buyer searching for "Retatrutide" gets zero hits on Particle's catalog unless they happen to know about GLP-3. The buyer who knows the alias gets the cheapest Retatrutide per-mg in the market; the buyer who doesn't gets routed to a different vendor, or to nothing at all. The alias is functionally a discount available only to insiders.

For audit desks like vialaudit, codename catalogs make cross-vendor pricing comparisons harder. Our /peptides-index page matches catalog SKUs against a canonical compound list; codename-only listings require a manual mapping step that doesn't generalize. We've added Particle's GLP-3 to the Retatrutide canonical list explicitly. Summit Biotech's R-10mg, T-30mg, and Sema-1 are added as of this article. The mapping is maintained at data/pricing/aliases.json in the source repo.

For regulators, the codename pattern is operational evidence that prior enforcement worked at the naming layer and not at the supply layer. The Summit Research Peptides → Summit Biotech rebrand removed Tirzepatide and Semaglutide from the catalog text but did not remove them from the warehouse. Future warning-letter templates will need to cite COA URLs and chemical identifiers, not just SKU display names, to bind the operator on the chemistry that is actually being shipped.

FAQ

Is using a code name on a research-peptide listing illegal?

Not on its face. SKU naming is a marketing decision; vendors can call a product whatever they want. What can be problematic is undisclosed identity — a listing that does not surface the chemical name, CAS number, or research identifier anywhere on the product page is concealing material information from buyers. There is no specific FDA rule against codenames, but a codename combined with no chemistry disclosure is the pattern the agency's recent enforcement letters have been built on.

How do I find the real compound behind a codename?

Three steps, in order. First, click the COA link if present — the lab's filename usually contains the actual molecule. Second, search the product page text for any string matching LY[0-9]+, NN[0-9]+, or a CAS number — those are research identifiers and resolve to a single named compound on Wikipedia or PubChem. Third, compare the codename's per-mg price to the named market on a price index like /peptides-index. Those three signals together resolve almost every alias.

Are all codename listings sketchy?

No. Some are legitimate naming conventions for blends or in-house formulations — Summit Biotech's KLOW and GLOW listings are multi-compound stacks where a code name is genuinely the cleanest label. The audit-relevant filter is whether the codename substitutes for a single FDA-cited compound name. KLOW (a stack) is fine. R-10mg (one molecule, no disclosed name) is the pattern this article covers.

Why didn't Particle and Summit Biotech just stop selling these compounds?

Because the compounds are the highest-margin SKUs in the market. Retatrutide, Tirzepatide, and Semaglutide are also the most search-traffic-heavy peptides on the catalog. Removing them would remove most of the operator's revenue. Renaming them keeps the revenue, costs almost nothing, and pushes the regulatory risk onto the buyer — who is now ordering a compound the catalog declines to name.

Sources

• Eli Lilly Retatrutide clinical trial registration: NCT04881760 — LY3437943 is the chemical identifier used on every Eli Lilly trial of the triple-agonist GLP-1 / GIP / glucagon-receptor compound.
• FDA Warning Letter, Summit Research Peptides (Dec 10, 2024): https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024 — cites Tirzepatide and Semaglutide on the vendor's website by name; triggered the rebrand to summitbiotechusa.com.
• Foley & Lardner, "FDA Targets GLP-1 Providers with Warning Letters" (Dec 2024): https://www.foley.com/insights/publications/2024/12/fda-targets-glp-1-providers-with-warning-letters/ — context on the warning-letter template and the named-compound matching the agency uses.
• Particle Peptides GLP-3 product page: https://particlepeptides.com/en/buy-peptides/95-glp-3-10mg.html — the page itself reads "GLP-3 (LY3437943)" in the description copy.
• Summit Biotech catalog (authenticated capture, May 2026): product IDs fbb34a1e-e17b-4b7b-8d81-e44749337e8d (Sema-1), cd49626e-6b5b-4089-8a2b-12cdb4da2cb8 (R-10mg), 5c061fdc-7249-443d-927a-458925620613 (T - 30mg), d8a44912-37a0-4600-8f22-42495dbe61b1 (T - 60mg), c03ab27f-24f2-484e-9b40-aad9ac7d69ec (Cagri), c52f0bcd-f3f2-49ad-96d4-33854c0b354c (Tesa 20mg), 294bff3a-da55-4c3a-98fc-24ec66d00593 (**-31 - 10mg). Each record carries a Janoshik or Vanguard COA URL whose filename spells out the actual molecule.
• Internal: data/audit/round-66/findings/summit-biotech-deep-dive.md — code-name table with prices, Geneza supply chain notes, login-wall posture documentation.
• Internal: data/audit/round-66/findings/decisive-evidence.md — cross-vendor fingerprint scan that surfaced the broader investigation context for this article.
• Internal: data/audit/round-66/technical/summit-biotech/products.json — the captured Summit Biotech catalog payload.
• Internal: Particle Peptides vendor profile — already documents the GLP-3 → Retatrutide alias as a transparency finding.
• Internal: How to spot a hostname-aliased peptide vendor — the hostname-level analog to the catalog-level pattern this piece documents.